Literature DB >> 4479517

Serum creatine phosphokinase isoenzyme (CPK2) in myositis. A report of six cases.

K Brownlow, F R Elevitch.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4479517

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  8 in total

1.  Myocardial creatine kinase isoenzyme in serum after subarachnoid haemorrhage.

Authors:  G Fabinyi; D Hunt; L McKinley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-08       Impact factor: 10.154

Review 2.  Creatine phosphokinase-MB (CPK-MB) and the diagnosis of myocardial infarction.

Authors:  P M Guzy
Journal:  West J Med       Date:  1977-12

3.  Diagnostic value of creatine phosphokinase (CPK) isoenzymes in the absence of elevated total CPK.

Authors:  W L Ruff; R Worrell; K Ng
Journal:  J Natl Med Assoc       Date:  1979-04       Impact factor: 1.798

Review 4.  Creatine kinase: race-gender differences in patients hospitalized for suspected myocardial infarction.

Authors:  J C Cook; E Wong; L J Haywood
Journal:  J Natl Med Assoc       Date:  1990-04       Impact factor: 1.798

5.  Dermatomyositis, suxamethonium action and atypical plasmacholinesterase.

Authors:  O Eielsen; J Stovner
Journal:  Can Anaesth Soc J       Date:  1978-01

6.  Increased MB-creatine kinase isoenzymes in an alcoholic population.

Authors:  R J Siegel; M Kligerman; L J Haywood; W E Shell
Journal:  J Natl Med Assoc       Date:  1985-06       Impact factor: 1.798

7.  [Studies of activity kinetic of isoenzyme CK-MB in serum after myocardial infarction (author's transl)].

Authors:  D Neumeier; W Prellwitz; P Sandel; M Knedel
Journal:  Klin Wochenschr       Date:  1978-05-01

8.  Creatine kinase-(MB) and hepcidin as candidate biomarkers for early diagnosis of pulmonary tuberculosis: a proof-of-concept study in Lambaréné, Gabon.

Authors:  Paulin N Essone; Bayode R Adegbite; Marien J M Mbadinga; Armel V Mbouna; Fabrice Lotola-Mougeni; Ayodele Alabi; Jean R Edoa; Bertrand Lell; Abraham S Alabi; Ayola A Adegnika; Michael Ramharter; Joel F D Siawaya; Martin P Grobusch; Peter G Kremsner; Selidji T Agnandji
Journal:  Infection       Date:  2022-02-08       Impact factor: 7.455

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.